News

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for success – – First patient enrolled…

2 years ago

Applied Molecular Transport Appoints Charlene Banard to its Board of Directors

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical…

2 years ago

OrthoPediatrics’ ApiFix® System Selected as 2022 MDEA Finalist

WARSAW, Indiana, April 06, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company exclusively focused…

2 years ago

Lower vaccination rates among people who use drugs could lead to serious outcomes from COVID-19

VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- As many jurisdictions in Canada begin to ease public health measures…

2 years ago

Sema4 Achieves HITRUST CSF Certification

HITRUST CSF Certification validates Sema4’s commitment to meeting key healthcare regulations and protecting sensitive informationSTAMFORD, Conn., April 06, 2022 (GLOBE…

2 years ago

Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA

FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused…

2 years ago

Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial

Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared to placebo in adults with narcolepsyNew data…

2 years ago

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

- Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company - - This Phase 1 Healthy…

2 years ago

BetterLife’s BETR-001 Demonstrates BETR-001 Anti-depressant Activity in Preclinical Models of Depression

VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…

2 years ago

Collegium Appoints Neil McFarlane to its Board of Directors

STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today…

2 years ago